tirzepatide surmount 3 SURMOUNT-1 three year efficacy outcomes just presented at #ObesityWeek2024 👀 📉Sustained weight loss of 22.9% or an average 54lbs over years 🔽94% reduction in risk of progression to diabetes. Number tirzepatide phase 3 trial 80

Abstract Aim: Insulin-like growth factor-1 (IGF-1) is an important hypertrophic and cell cycle progression factor for a number of cell types

We also know there are reports emerging of potential complications, such as weight regain when you stop taking GLP-1 medicines, and some very rare risks, such as potential vision loss in one eye

Talking To Your Healthcare Provider (HCP) Discussing your weight and health with your healthcare provider is a good first step

Nutrients, 12(9), 2502

Sin embargo, se recomienda monitoreo cuidadoso de los niveles de enzimas pancreticas en pacientes tratados con GLP-1RA

With pens, you may need to look through the viewing window on the cartridge